Business
Next-level cannabis investor forum MjMicro debuts in NYC on June 25
Next-level cannabis investor forum MjMicro debuts in NYC on June 25.
About this update from Decentral Life, Inc.
[{"type":"text","content":"\nNEW YORK, May 14, 2019 (GLOBE NEWSWIRE) -- via CannabisNewsWire – MjMicro Conference (www.mjmicro.com), the next-level investor forum for publicly traded cannabis companies, debuts in New York City on June 25 at the Westin Grand Central Hotel. This one-day conference provides an exceptional opportunity for cannabis-related public entities to connect with private capital investors and also features presentations from noted industry experts.\n The MjMicro Conference is an invitational networking forum exclusively created to enable best-in-class and emerging public companies in the cannabis industry to meet with high-net-worth investors, venture funds and family offices, helping drive private investment capital into public entities, promote trading liquidity, and increase media and analyst coverage. “Our goal is to provide both the most exciting and diverse range of public company investment opportunities, ranging from micro to mid-cap companies that have proof of concept, revenue streams, audited financials and public market liquidity,” noted George Jage, president of MjLink.com and producer of MjMicro. “This event creates direct C-suite access for investors to provide insight into their vision, strategy and performance.” Confirmed presenting companies include 1933 Industries, CannAmerica Brands, Cannex Capital Holdings, Cardiol Therapeutics, Dixie Brands, Emerald Health Therapeutics, FSD Pharma, Helix TCS Inc., High Tide Inc., House of Jane, Province Brands of Canada, MJ Freeway, Tauriga Sciences, United Cannabis Corp., and Vireo Health. “FSD Pharma, a spotlight presenter, is endemic of the exciting opportunities in the market. They are a Canadian licensed producer developing cutting-edge technology and conducting research related to the treatment of chronic pain, fibromyalgia and other medical conditions that are typically treated with pharmacological applications,” noted Todd Markey, director of investor relations at MjMicro. “There are over 400 cannabis-related public companies in the market today, and we project that anywhere between 100 and 200 others will get listed in the next 24 months,” stated Jage. “There has been a race for cannabis companies to access the public capital markets, but the industry lacks the access to institutional capital that you would expec...